Venturelab
close

Scailyte closes pre-series A financing round

09.06.2020 15:38, Gianmaria Sbetta

Scailyte raises CHF 3.1 million in a pre-series A financing round led by Swisscom Ventures to further advance its biomarker discovery platform.

Scailyte discovers ultrasensitive biomarkers and develops in-vitro diagnostics using single-cell technologies and their proprietary single-cell data analysis platform ScaiVisionTM.
ScaiVisionTM offers the best-in-class analysis of complex single-cell data to enhance biomedical research, pharmaceutical discovery and precision diagnostics. Besides developing its own in vitro diagnostic (IVD) applications, Scailyte also offers its biomarker discovery services to companies aiming to complement and enrich their analysis by adding the single-cell perspective.

We are continuously developing and utilizing our data analytics platform ScaiVisionTM for biomarker discovery from single-cell data,” says Peter Nestorov, CEO of Scailyte AG.
The current version covers all aspects of processing, handling and interpreting single-cell proteomics data (mass and flow cytometry), as well as a core functionality for analyzing single-cell transcriptomics data. This allows us to accelerate biomedical discovery and enable the next generation of precision diagnostics. With the support of strong partners like Swisscom Ventures, 4FO and HEMEX, we will continue to grow in the fast-emerging Single-Cell Analysis field, enabling various clinical applications of single-cell data“.

The raised capital will be used to further build upon Scailyte’s biomarker and IVD pipeline, and drive the development of the first clinical applications using single-cell biomarkers.

Scailyte received support from Venture Kick in 2017 and was selected as Venture Leader Life Sciences and TOP 100 in 2019. 

"Venturelab has been supporting Scailyte from the very beginning with valuable and actionable advice, training and most importantly by providing access to an amazing network of investors and entrepreneurs. We are thankful for this support and appreciate the strong dedication of the Venturelab team to help Swiss startups in becoming unicorns"  Peter Nestorov, CEO of Scailyte




Source: Scailyte Press Release

Scailyte AG: Predictive biomarkers, fueling next-gen pharma pipelines.

Scailyte pioneers single-cell biomarker discovery as this technology enters clinical trials. Our proprietary computational platform creates high-value IP and clinical assets in autoimmunity and oncolo... Read more